Neoadjuvant semaglutide showed no benefit in weight loss, diabetes remission or safety in a cohort of patients who underwent metabolic and bariatric surgery, according to study results published ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

A new study compared the effectiveness of weight-loss drugs tirzepatide and semaglutide, finding tirzepatide leads to greater weight loss and waist reduction. Doctors shared insights.

The diabetes and weight loss drug semaglutide may also reverse signs of liver disease. That’s the headline result of a new clinical trial that tested the popular medication in patients with MASH ...

Semaglutide was initiated at a dose of 0.25 mg once weekly, and the dose was increased every 4 weeks in accordance with recommended dosing (from 0.25 mg to 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg ...

Semaglutide drugs have grown in popularity, resulting in shortages of Ozempic and Wegovy. To help meet demand, some licensed compounding pharmacies have begun producing compounded semaglutide.

Compounded semaglutide is a non-FDA-approved alternative to products that contain semaglutide, such as Ozempic. Learn how the safety and efficacy of compounded semaglutide compares with Ozempic.

Patients are being hospitalized with severe complications after accidentally overdosing on compounded semaglutide injections, the FDA has warned. Reported adverse effects include gastrointestinal ...

The analysis also revealed how many people may meet multiple criteria to take semaglutide. Nearly 32 million adults qualify for two or all three of the drug’s uses, which include managing weight ...

Taking semaglutide may lead to a slight increase in heart rate — typically by two to three beats per minute, based on trials sponsored by Novo Nordisk using 0.5 and 1 mg doses of semaglutide.

Being prescribed semaglutide for diabetes or weight management is associated with an increased risk, up to seven times, of developing a relatively rare form of untreatable blindness, sometimes ...